menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Holding Court in Pulmonary Hypertension: Should All Adult Fontan Patients Be Placed on Group 1 PAH Therapy?

Do you have adult Fontan patients? Do you know if their pulmonary hypertension should be treated with Group 1 vasodilators? Watch this complex case to make a decision!

Live Broadcast
1.00 available credits
Information
October 11, 2022
01:30 PM - 02:30 PM EDT
Virutal
ReachMD Healthcare Image
Details
Presenters
Comments

  • Overview

    Patients with congenital heart disease are increasingly surviving into adulthood. For patients with single ventricle anatomy, pulmonary blood flow is dependent on central venous pressure with little or no ventricular support. Patients who have undergone Fontan surgery and progress to adulthood frequently develop increased pulmonary vascular resistance, which impacts ventricular function in a precapillary pulmonary hypertension phenotype.

    The court case will explore the central question of should these patients be placed on Group 1 vasodilator therapy. This pro/con debate will place you, the audience, in the role of the juror to decide the outcome. Evidence is presented, and expert witnesses queried on the pluses and minuses of this therapeutic approach to maintaining physical function and quality of life in Fontan patients.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including physicians, nurses, and pharmacists involved in the management of patients with congenital heart disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the fundamental aspects of adult congenital heart disease with univentricular physiology
    • Debate the hemodynamic aspects of Fontan physiology and its failure
    • Review current information on the use of Group 1 vasodilator therapies in the adult Fontan
    • Discuss the negative aspects of Group 1 vasodilator therapy in the adult Fontan patient

  • Accreditation and Credit Designation Statements

     

     

     

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

    The following faculty have disclosed:

    Jean Elwing, MD, faculty for this educational event, receives research funds from Actelion/Janssen, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer, Acceleron, Altavant, Arena, Aerovate and Lung LLC; and receives consulting fees from Acceleron, Janssen, United Therapeutics, Altavant, Aerovate, Bayer, Gossamer Bio and Liquidia.

    Richard Krasuski, MD, faculty for this educational event, receives research funds from Actelion/ Janssen, Edwards Lifesciences, Corvia, CryoLife and Medtronic; and receives consulting fees from Actelion/ Janssen and Gore Medical.

    Jamil A. Aboulhosn, MD, faculty for this educational event, receives research funds from Edwards Lifesciences, Abbott Inc, Janssen and Medtronic; and receives consulting fees from Medtronic and Edwards Lifesciences.

    Joseph Kay, MD, faculty for this educational event, TBD

    Alexander Opotowsky, MD, MMSc, faculty for this educational event, TBD

    Wayne J. Franklin, MD, FACC, faculty for this educational event, has no relevant financial relationships with ineligible companies

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated. 

  • Acknowledgment

     

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

    This activity is supported by an educational grant from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Facebook Comments

Details
Presenters
Comments
Recommended

  • Overview

    Patients with congenital heart disease are increasingly surviving into adulthood. For patients with single ventricle anatomy, pulmonary blood flow is dependent on central venous pressure with little or no ventricular support. Patients who have undergone Fontan surgery and progress to adulthood frequently develop increased pulmonary vascular resistance, which impacts ventricular function in a precapillary pulmonary hypertension phenotype.

    The court case will explore the central question of should these patients be placed on Group 1 vasodilator therapy. This pro/con debate will place you, the audience, in the role of the juror to decide the outcome. Evidence is presented, and expert witnesses queried on the pluses and minuses of this therapeutic approach to maintaining physical function and quality of life in Fontan patients.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including physicians, nurses, and pharmacists involved in the management of patients with congenital heart disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the fundamental aspects of adult congenital heart disease with univentricular physiology
    • Debate the hemodynamic aspects of Fontan physiology and its failure
    • Review current information on the use of Group 1 vasodilator therapies in the adult Fontan
    • Discuss the negative aspects of Group 1 vasodilator therapy in the adult Fontan patient

  • Accreditation and Credit Designation Statements

     

     

     

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

    The following faculty have disclosed:

    Jean Elwing, MD, faculty for this educational event, receives research funds from Actelion/Janssen, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer, Acceleron, Altavant, Arena, Aerovate and Lung LLC; and receives consulting fees from Acceleron, Janssen, United Therapeutics, Altavant, Aerovate, Bayer, Gossamer Bio and Liquidia.

    Richard Krasuski, MD, faculty for this educational event, receives research funds from Actelion/ Janssen, Edwards Lifesciences, Corvia, CryoLife and Medtronic; and receives consulting fees from Actelion/ Janssen and Gore Medical.

    Jamil A. Aboulhosn, MD, faculty for this educational event, receives research funds from Edwards Lifesciences, Abbott Inc, Janssen and Medtronic; and receives consulting fees from Medtronic and Edwards Lifesciences.

    Joseph Kay, MD, faculty for this educational event, TBD

    Alexander Opotowsky, MD, MMSc, faculty for this educational event, TBD

    Wayne J. Franklin, MD, FACC, faculty for this educational event, has no relevant financial relationships with ineligible companies

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated. 

  • Acknowledgment

     

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

    This activity is supported by an educational grant from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Facebook Comments

Recommended

Schedule30 Sep 2023
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended